Clearpoint Neuro Inc (CLPT) Peer Comparison

$15.55

$-0.39 (-2.45%)

As on 28-Aug-2026 16:00EDT

Market cap

$474 Mln

Revenue (TTM)

$42 Mln

P/E Ratio

--

P/B Ratio

45

Div. Yield

0 %

Edit

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	474	12,753	10,906	9,948	9,762
Revenue ($ Mln)	42	1,505	613	785	2,589
Net Profit ($ Mln)	-34.57	160.59	-188.05	41.54	222.40
Net Margin (%)	-81.76	10.67	-30.68	5.29	8.59
RoE (%)	-178.19	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	45.04	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	42.28	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	15.81	483.98	127.96	384.30	1,245.50
Gross Profit	22.69	942.44	393.22	347.62	1,343.60
Operating Expenses	57.51	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-31.04	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-34.58	203.83	-192.83	52.15	350.40
Provision for Tax	-0.02	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-34.57	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	10.78	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	65.65	210.18	135.71	705.49	2,116.80
Current Liabilities	10.31	233.78	102.33	132.66	961.30
Total Liabilities	97.75	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	38.01	630.60	404.74	1,749.63	7,231.50
Current Assets	48.73	1,344.12	515.78	1,200.55	3,020.50
Total Assets	97.75	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	63.95	212.71	102.84	690.94	1,203.70
Net Current Assets	38.62	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-23.93	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	0.62	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	50.18	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-44.34	11.76	-22.53	1.79	8.98
ROE (%)	-178.19	10.86	-28.10	1.97	3.04
ROA (%)	-41.37	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-72.91	13.63	-30.58	9.87	-5.99
Net Margin (%)	-81.76	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	25.86	17.55	41.55	16.49	1.37
EBIT Growth (%)	-39.48	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-55.54	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-47.50	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-48.34	17.33	-12.65	2.16	2.19

Valuation Ratios

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-15.17	68.93	-34.59	189.42	--
Price / Book Value	13.82	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-19.16	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	4.66	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.02	0.01	0.00	0.01	0.06
Current Ratio	4.73	5.75	5.04	9.05	3.14
Quick Ratio	3.87	3.86	4.46	7.64	2.33
Interest Coverage	-7.56	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Clearpoint Neuro Inc (CLPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	22.13	12.65	22.67	20.09	17.06
Asset Turnover	0.51	0.74	0.59	0.26	0.24
Receivable days	59.16	46.54	60.95	72.41	65.39
Inventory Days	194.69	331.92	193.84	146.53	221.09
Payable days	33.20	26.16	60.19	29.05	37.02
Cash Conversion Cycle	220.64	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly